Masimo reported strong Q3 2022 results, with consolidated revenue of $549.3 million, a 78.7% increase compared to Q3 2021. Healthcare revenue grew by 6.4% to $327.2 million, and non-healthcare revenue was $222.1 million. GAAP net income was $37.9 million, or $0.70 per diluted share, while non-GAAP net income was $53.9 million, or $1.00 per diluted share.
Consolidated revenue reached $549 million.
Healthcare revenue was $327 million, demonstrating 6% reported growth and 10% constant currency growth.
Non-healthcare revenue amounted to $222 million.
GAAP net income was $37.9 million, or $0.70 per diluted share; non-GAAP net income was $53.9 million, or $1.00 per diluted share.
The Company provided the following estimates for its fourth quarter and full year 2022 guidance: